BioMarin Pharmaceutical Inc. / Fundamentals
Income statement
- Net revenue
€2.61B - Cost of goods sold
€534.16M - Gross profit
€2.07B - SG&A expenses
€817.53M - R&D expenses
€578.68M - EBITDA
€763.60M - D&A
€42.51M - EBIT
€661.96M - Interest expenses
€2.56K - EBT
€716.51M - Tax expenses
€155.92M - Net income
€560.59M
Cash flow statement
- Net deferred tax
€99.22M - Non-cash items
-€172.90M - Changes in working capital
-€58.78M - Operating cash flow
€654.02M - Capex
€64.26M - Other investing cash flow
-€2.22M - Net investing cash flow
€16.56M - Total cash dividends paid
€0.00 - Issuance of common stock
-€24.66M - Debt repayment
-€422.15M - Other financing cash flow
-€44.72M - Net financing cash flow
-€460.29M - Foreign exchange effects
-€4.16M - Net change in cash
€206.13M - Cash at end of period
€1.04B - Free cash flow
€718.28M
Balance sheet
- Cash and cash equivalents
€1.04B - Cash and short-term investments
€1.22B - Total receivables
€730.00M - Inventory
€1.14B - Other current assets
€151.13M - Total current assets
€3.25B - Property, plant & equipment
€878.87M - Goodwill
€167.35M - Intangible assets
€204.38M - Long-term investments
€433.80M - Other non-current assets
€212.55M - Total non-current assets
€3.11B - Total assets
€6.36B - Accounts payable
€265.09M - Short-term debt
€6.57M - Other current liabilities
€300.53M - Total current liabilities
€583.63M - Long-term debt
€508.50M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€126.94M - Total non-current liabilities
€635.43M - Total liabilities
€1.22B - Common stock
€163.77K - Retained earnings
€197.48M - Other equity
-€38.01M - Total equity
€5.14B - Total liabilities and shareholders' equity
€6.36B
Company information
- Market capitalization
€9.02B - Employees
3K - Enterprise Value
€10.51B
Company ratios
- Gross margin
-
79.5% Much better than peer group: -5,356.6% - EBITDA margin
-
29.3% Much worse than peer group: 70,937.0% - EBIT margin
-
25.4% Much worse than peer group: 75,335.7% - EBT margin
-
27.5% Much worse than peer group: 14,330.9% - Net margin
-
21.5% Much worse than peer group: 76,959.8% - ROE
-
10.9% Much better than peer group: -56.9% - ROA
-
8.8% Much better than peer group: -25.1% - Asset turnover
-
41.0% Better than peer group: 35.4% - FCF margin
-
22.6% Much worse than peer group: 74,308.0% - FCF yield
6.5% - Efficiency ratio
70.7% - Net sales per employee
-
€857.02K - Net income per employee
-
€184.41K